NCT02692599View on ClinicalTrials.gov

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

1,150

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

July 15, 2016

Conditions
Mumps
Interventions
BIOLOGICAL

investigational live attenuated mumps vaccine

The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

BIOLOGICAL

control live attenuated mumps vaccine

The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.

Trial Locations (1)

072650

Dingxing County Center for Disease Control and Prevention, Baoding

All Listed Sponsors
lead

Sinovac (Dalian) Vaccine Technology Co., Ltd.

INDUSTRY

NCT02692599 - Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants | Biotech Hunter | Biotech Hunter